The role of PET Scan in gastrointestinal stromal tumors;Place de l'imagerie par Tomographie par Émission de Positons pour les tumeurs stromales gastro-intestinales

Gastroenterologie Clinique et Biologique

Volumn 31, Issue 6-7, 2007, Pages 585-593

  Alberini, Jean Louis ^a   Al Nakib, Malik ^a   Wartski, Myriam ^a   Gontier, Éric ^a   Cvitkovic, Frédérique ^a   Rixe, Olivier ^b   Rougier, Philippe ^c   Pecking, Alain Paul ^a  

^a CENTRE RENÉ HUGUENIN   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c HÔPITAL AMBROISE PARÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB;

ABDOMEN; CANCER STAGING; CANCER THERAPY; CLINICAL STUDY; COMPUTER ASSISTED TOMOGRAPHY; DECISION MAKING; DENSITY; EVALUATION; GASTROINTESTINAL STROMAL TUMOR; HUMAN; MOLECULE; MONITORING; MORPHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROSPECTIVE STUDY; REVIEW; THERAPY EFFECT; TREATMENT RESPONSE; TUMOR GROWTH;

EID: 34447631707     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0399-8320(07)89435-8     Document Type: Short Survey

References (50)

1. Mazur M, Clark H. Gastric stromal tumors: reappraisal of histogenesis. Am J Surg Pathol 1983;7:507-19.
2. Ray-Coquard I, Le Cesne A, Michallet V, Boukovinas I, Ranchere D, Thiesse P et al. Tumeurs Stromales du tractus digestif : actualités 2003. Bull cancer 2003;90:69-76.
3. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001;344:1052-6.
4. Bourguet P, Groupe de travail des SOR. Standards, Options et Recommandations FNCLCC. Utilisation de la Tomographie par Emission de Positons au [18F]-FDG en cancérologie. Bull cancer 2003;90:S51-5.
5. Som P, Atkins H, Bandoypadhyay D, Fowler JS, MacGregor RR, Matsui K et al. A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): non toxic tracer for rapid tumor detection. J Nucl Med 1980;21:670-5.
6. Kitagawa Y, Sano K, Nishizawa S, Nakamura M, Ogasawara T, Sadato N et al. FDG-PET for prediction of tumour aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer. Eur J Nucl Med Mol Imaging 2003;30:63-71.
7. Bos R, van Der Hoeven JJ, van Der Wall E, van Der Groep P, van Diest PJ, Comans EF et al. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 2002;20:379-87.
8. Jager PL, Gietema JA, van der Graaf WT. Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET. Nucl Med Commun 2004;25:433-8.
9. Choi H, Charnsangavej C, de Castro Faria S, Tamm E, Benjamin R, Johnson M et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. Am J Roentgenol 2004;183:1619-28.
10. rd, Eary JF. (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin Cancer Res 2000;6:1279-87.
11. Gayed I, Vu T, Iyer R, Johnson M, Macapinlac H, Swanston N et al. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med 2004;45:17-21.
12. Salaun P, Grewal R, Dodamane I, Yeung H, Larson S, Strauss H. An analysis of the 18F-FDG uptake pattern in the stomach. J Nucl Med 2005;46:48-51.
13. Koga H, Sasaki M, Kuwabara Y, Hiraka K, Nakagawa M, Abe K et al. An analysis of the physiological FDG uptake pattern in the stomach. Ann Nucl Med 2003;17:733-8.
14. Blay JY, Bonvalot S, Casali P, Choi H, Debiec-Richter M, Dei Tos AP et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol 2005;16:566-78.
15. Blay J, Landi B, Bonvalot S, Monges G, Ray-Coquard I, Duffaud F et al. Recommendations for the management of GIST patients. Bull Cancer 2005;92:907-18.
16. Vander Noot M, Eloubeidi M, Chen V, Eltoum I, Jhala D, Jhala N et al. Diagnosis of gastrointestinal tract lesions by endoscopic ultrasound-guided fine-needle aspiration biopsy. Cancer 2004;25:157-63.
17. Ng E, Pollock R, Romsdahl M. Prognostic implications of patterns of failure for gastrointestinal leiomyosarcomas. Cancer 1992;69:1334-41.
18. Burkill G, Badran M, Al-Muderis O, Meirion Thomas J, Judson I, Fisher C et al. Malignant gastrointestinal stromal tumor: distribution, imaging features, and pattern of metastatic spread. Radiology 2003;226:527-32.
19. Antoch G, Kanja J, Bauer S, Kuehl H, Renzing-Koehler K, Schuette J et al. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med 2004;45:357-65.
20. Goerres GW, Stupp R, Barghouth G, Hany TF, Pestalozzi B, Dizendorf E et al. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate. Eur J Nucl Med Mol Imaging 2005;32:153-62.
21. Suzuki A, Kawano T, Takahashi N, Lee J, Nakagami Y, Miyagi E et al. Value of 18F-FDG in the detection of peritoneal carcinomatosis. Eur J Nucl Med Mol Imaging 2004;31:1413-20.
22. Sandrasegaran K, Rajesh A, Rushing D, Rydberg J, Akisik F, Henley J. Gastrointestinal stromal tumors: CT and MRI findings. Eur Radiol 2005;15:1407-14.
23. Stroobants S, Goeminne J, Seegers M, Dimitrijevic S, Dupont P, Nuyts J et al. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 2003;39:2012-20.
24. Demetri G, von Mehren M, Blanke C, Van den Abbeele A, Eisenberg B, Roberts P et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80.
25. Landi B, Lecomte T, Berger A, Cellier C. Traitement des tumeurs stromales digestives. Gastroenterol Clin Biol 2004;28:893-901.
26. Demetri G, Desai J, Fletcher J, Morgan J, Fletcher C, Kazanovicz A et al. SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST). J Clin Oncol (proceedings) 2004;22:3001.
27. Joensuu H. Treatment of inoperable gastrointestinal stromal tumor (GIST) with Imatinib (Glivec, Gleevec). Med Klin (Munich) 2002;97(Suppl 1):28-30.
28. Verweij J, Casali P, Zalcberg J, Le Cesne A, Reichardt P, Blay J et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004;364:1127-34.
29. Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan R, Rubienstein L et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
30. Van den Abbeele A, Badawi R. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer 2002;38(Suppl 5):S60-5.
31. Holdsworth C, Manola J, Badawi R, Israel D, Blanke C, Von Mehren M et al. Use of computerized tomography (CT) as an early prognostic indicator of response to imatinib mesylate (IM) in patients with gastrointestinal stromal tumors (GIST). J Clin Oncol (proceedings) 2004;22:3011.
32. Chen MY, Bechtold RE, Savage PD. Cystic changes in hepatic metastases from gastrointestinal stromal tumors (GISTs) treated with Gleevec (imatinib mesylate). Am J Roentgenol 2002;179:1059-62.
33. Joensuu H, Fletcher C, Dimitrijevic S, Silberman S, Roberts P, Demetri G. Management of malignant gastrointestinal stromal tumours. Lancet Oncol 2002;3:655-64.
34. Shankar S, Vansonnenberg E, Desai J, Dipiro PJ, Van Den Abbeele A, Demetri GD. Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate. Radiology 2005;235:892-8.
35. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma A et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999;35:1773-82.
36. O'Connell M, Therasse P. PET-CT modification of RECIST guidelines. J Natl Cancer Inst 2004;96:801-2.
37. van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001;358:1421-3.
38. van den Abbeele A. 18F-FDG-PET predicts response to imatinib mesylate (Gleevec) in patients with advanced gastrointestinal stromal tumors (GIST). J Clin Oncol (proceedings) 2002;20:1610.
39. Boren J, Cascante M, Marin S, Comin-Anduix B, Centelles JJ, Lim S et al. Gleevec (STI571) influences metabolic enzyme activities and glucose carbon flow toward nucleic acid and fatty acid synthesis in myeloid tumor cells. J Biol Chem 2001;276:37747-53.
40. Cullinane C, Dorow D, Kansara M, Conus N, Binns D, Hicks R et al. An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development. Cancer Res 2005;65:9633-6.
41. Grimpen F, Yip D, Mc Arthur G, Waring P, Goldstein D, Loughrey M et al. Resistance to imatinib, low-grade FDG-avidity on PET, and acquired KIT exon 17 mutation in gastrointestinal stromal tumour. Lancet Oncol 2005;6:724-7.
42. Fletcher C, Berman J, Corless C, Gorstein F, Lasota J, Longley BJ et al. Diagnosis of GIST, a consensus approach. Hum Pathol 2002;33:459-65.
43. Beyer T, Antoch G, Bockisch A, Stattaus J. Optimized intravenous contrast administration for diagnostic whole-body 18F-FDG PET/CT. J Nucl Med 2005;46:429-35.
44. Dileo P, van Den Abbeele AD, Manola J, Desai J, Morgan JA, George S et al. Qualitative assessment of 18FDG-PET correlates with clinical benefit in patients (pts) with imatinib mesylate (IM)-resistant GIST treated with the multi-targeted tyrosine kinase inhibitor SU11248 (abstract). Gastrointestinal Cancers Symposium ASCO 2005:8.
45. van den Abbeele A, Melenevsky Y, de Vries D, Manola J, Tetrault R, Baum C et al. Predicting kinase target inhibition with SU11248 by FDG-PET in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (I-R GIST). J Clin Oncol (proceedings) 2005;23:9006.
46. van den Abbeele A, Badawi R, Manola J, Morgan J, Desai J, Kazanovicz A et al. Effects of cessation of imatinib mesylate (IM) therapy in patients (pts) with IM-refractory gastrointestinal stromal tumors (GIST) as visualized by FDG-PET scanning. J Clin Oncol (proceedings) 2004;22:3012.
47. Janicek M. Imaging responses to Imatinib mesylate (Gleevec, STI571) in gastrointestinal stromal tumors (GIST): vascular perfusion patterns with Doppler ultrasound (DUS) and dynamic infrared imaging (DIRI). J Clin Oncol (proceedings) 2002;20:333.
48. Lassau N, Lamuraglia M, Chami L, Leclere J, Bonvalot S, Tursz T et al. Gastrointestinal stromal tumours treated by imatinib: monitoring response with contrast enhanced ultrasound. Am J Roentgenol 2006;187:1267-73.
49. De Giorgi U. Effect of angio-echography with a second-generation contrast agent to assess tumor response to imatinib treatment in patients with advanced gastrointestinal stromal tumor (GIST): Comparison with computerized tomography (CT). J Clin Oncol (proceedings) 2004;22:4216.
50. Bono P, Krause A, von Mehren M, Heinrich M, Blanke C, Dimitrijevic S et al. Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib. Blood 2004;103:2929-35.